No profile data available.
Candel Therapeutics, Inc. (CADL) is a healthcare company in the additional cancer treatment drugs industry, based in Needham, United States, with about 55 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$38.18 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $760.59 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Candel Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$760.59 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Cullinan Therapeutics, Inc. (CGEM), Replimune Group, Inc. (REPL), ArriVent BioPharma, Inc. (AVBP), Verastem, Inc. (VSTM).